2022 ESC冠心病研究进展速递

详细信息

收稿日期: 2022-09-13

刊出日期: 2022-10-13

Clinical research progress of coronary heart disease at the 2022 annual congress of the European Society of Cardiology

- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Received Date: 13 September 2022

Publish Date: 13 October 2022

摘要: 在2022年欧洲心脏病学会(ESC)年会上，冠心病领域的临床研究在介入治疗策略、抗栓治疗方案、心肌梗死后抗心脏重构治疗、冠状动脉无创影像学评估等方面均取得了一定进展。本文就其中的REVIVED-BCIS2研究、FRAME-AMI研究、RTC研究、PANTHER研究、TAILOR-PCI研究的预设二次分析结果以及EMMY研究作一简要介绍。
- 冠心病 /
- 心力衰竭 /
- 急性心肌梗死 /
- P2Y₁₂抑制剂 /
- 恩格列净
Abstract: At the 2022 annual congress of the European Society of Cardiology(ESC), clinical trials in the field of coronary heart disease have made some progress in interventional therapy strategy, antithrombotic therapy, anti-remodeling therapy after myocardial infarction, and non-invasive coronary imaging evaluation. Here, we present a brief review of the REVIVED-BCIS2 trial, FRAME-AMI trial, RTC trial, PANTHER trial, a pre-specified secondary analysis of the TAILOR-PCI trial, and the EMMY trial.
- coronary heart disease /
- heart failure /
- acute myocardial infarction /
- P2Y₁₂inhibitors /
- empagliflozin

[1]	Perera D, Clayton T, O'Kane PD, et al. Percutaneous revascularization for ischemic left ventricular dysfunction[J]. N Engl J Med, 2022. doi:10.1056/NEJMoa2206606.
[2]	ESC 2022. The FRAME-AMI trial-FFR vs. Angiography-guided PCI in AMI with multivessel disease[C]. Barcelona: 2022.
[3]	ESC 2022. Impact on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: a Meta-analysis of individual patient data from seven multicenter randomized clinical trials[C]. Barcelona: 2022.
[4]	ESC 2022. PANTHER-P2Y₁₂ inhibitor versus aspirin monotherapy in patients with coronary artery disease[C]. Barcelona: 2022.
[5]	Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: The TAILOR-PCI Randomized Clinical Trial[J]. JAMA, 2020, 324(8): 761-771.
[6]	ESC 2022. Genotype-guided oral P2Y₁₂ inhibitor therapy reduces cumulative ischemic events following percutaneous coronary intervention-A prespecified secondary analysis of the TAILOR-PCI Randomised Trial[C]. Barcelona: 2022.
[7]	ESC 2022. Empagliflozin in patients with acute myocardial infarction[C]. Barcelona: 2022.